Health Care · Surgical & Medical Instruments & Apparatus · OTC · CIK 1091596 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.00Day +11.11%Mkt cap $48M1Y −41.4%Off 52W high −69.0%Vol (1Y) 95.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,740 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover1.0d |
| 13F net flow (QoQ)+0.00% |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$4.1M |
| Earnings (TTM)-$2.4M |
| Net margin−75.8% |
| Sales growth 3Y209.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−49.2% |
| 1Y−41.4% |
| 3Y−16.7% |
| 5Y+122.2% |
| Since incept. (ann.)+14.6% |
Total return through 2026-07-29 · series begins 2017-10-06. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)95.4% |
| Ann. volatility (3Y)128.3% |
| Sharpe (1Y)−0.01 |
| Sharpe (3Y)0.53 |
| Max drawdown (1Y)−72.1% |
| Max drawdown (3Y)−79.8% |
| Beta (3Y vs SPY)−0.03 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Ancora Advisors LLC | 4,700 | $6,815 | 0.01% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | — | — | $1.3M | +168.8% |
| 2025-12-31 | 2026-03-30 | — | — | $1.1M | +177.8% |
| 2025-09-30 | 2025-10-30 | — | — | $1.0M | +178.2% |
| 2025-06-30 | 2025-07-31 | — | — | $700,202 | +92.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Product 48% · Aurix And Private Label Kits 43% · Aurix And Private Label Centrifuge Devices 5% · License 4%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
